Compare Google Inc (GOOG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs GeneDx Holdings Corp — how do they compare? Google Inc trades at $347.63 (market cap $4.24T), while GeneDx Holdings Corp trades at $67.69 (market cap $2.02B). The key difference: Google Inc is far larger — about 2099× GeneDx Holdings Corp's market cap, and Google Inc pays a 0.26% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and GeneDx Holdings Corp for 19 Days on average.
| GOOG | WGS | |
|---|---|---|
Market Cap | $4.24T | $2.02B |
Volume | 13,937,902 | 734,640 |
Sector | Media | Health |
52-Week High | $399.06 | $167.51 |
52-Week Low | $237.49 | $34.51 |
Typical Hold Time | 137 Days | 19 Days |
Enterprise Value | $4.13T | $2.05B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $350.02, up 0.76% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 32.8% net margins and consistent earnings beats, though significant capital expenditures have led to negative free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target, representing 24% upside potential from current levels.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors face risks from escalating capital spending, regulatory scrutiny, and multiple class-action lawsuits. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, supported by robust cash flow generation and expanding cloud revenue streams.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
